sirukumab

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 464392155

| type = mab

| image =

| alt =

| mab_type = mab

| source = u

| target = IL6

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 1194585-53-9

| ATC_prefix = L04

| ATC_suffix = AC15

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank = DB11803

| KEGG = D10080

| UNII = 640443FU93

| C=6450 | H=9926 | N=1690 | O=1998 | S=46

}}

Sirukumab (INN, USAN) (developmental code name CNTO-136, tentative brand name Plivensia) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab|publisher=American Medical Association|url=http://www.ama-assn.org/resources/doc/usan/sirukumab.pdf}} It acts against the proinflammatory cytokine Interleukin 6 (IL-6).{{cite journal | vauthors = Bartoli F, Bae S, Cometi L, Matucci Cerinic M, Furst DE | title = Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018 | journal = Expert Review of Clinical Immunology | volume = 14 | issue = 7 | pages = 539–547 | date = July 2018 | pmid = 29925278 | doi = 10.1080/1744666X.2018.1487291 | s2cid = 49330982 }}

Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor.

Clinical trials

=Rheumatoid arthritis=

It has started clinical trials.{{ClinicalTrialsGov|NCT00718718|A Study of the Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy}} and reported some phase II results.{{cite web | url = http://www.prnewswire.com/news-releases/interleukin-6-inhibitor-sirukumab-cnto-136-phase-2-data-show-promise-in-the-treatment-of-active-rheumatoid-arthritis-122579373.html | title = Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis | work = PR News Wire | publisher = Cision | date = 25 May 2011 }}

In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data.{{cite web | vauthors = House DW | url = http://seekingalpha.com/news/2987756-glaxo-says-top-line-results-positive-in-late-stage-study-of-sirukumab-in-rheumatoid-arthritis | title = Glaxo says top-line results positive in late-stage study of sirukumab in rheumatoid arthritis | work = Seeking Alpha | date = 16 December 2015 }}

By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints.{{cite web | url = http://www.medpagetoday.com/mastery-of-medicine/rheumatology-mastery-in-ra/62753 | title = IL-6 in RA: What Predicts Non-Progression? - High-risk patients showed most benefit with sirukumab | date = January 2017 }}

=Research=

The drug was previously under development for the treatment of depression.{{cite web | title = Sirukumab - Janssen Biotech | url = http://adisinsight.springer.com/drugs/800026523 | work = AdisInsight | publisher = Springer Nature Switzerland AG }}

References

Category:Janssen Biotech